Introduction {#s1}
============

Biodegradable polymeric nanoparticles (NPs) and nanosystems (NSs) are deemed to be very efficient drug delivery systems (DDSs) that are extremely safer than any other non-biodegradable polymers and lipids used for gene/drug delivery.^[@R1]-[@R4]^ The biodegradable polymers are also bioactive and hence can be used as polymer-therapeutics,^[@R5]-[@R8]^ which can also be exploited for targeted delivery of a wide range of small and large molecules (e.g., human growth hormone,^[@R9]^ insulin,^[@R10]^ anti-tumor agents,^[@R11]^ contraceptives,^[@R12]^ vaccines,^[@R13]^ anticancer drugs,^[@R14]^ and antibiotics^[@R15]^) in a controlled, sustained or pulsatile manner.^[@R16]^ It should be highlighted that the liberation of encapsulated/incorporated drugs from these polymers can be carefully controlled and the drug concentration in the target site is maintained within the therapeutic window.^[@R17]^ Biodegradable polymers are considered as ideal biomaterials for the development of controlled-/sustained-release DDSs as well as therapeutic devices such as degradable implants, impermanent prostheses, and degradable 3D scaffolds for tissue engineering. To develop effective therapeutic devices, one needs to use the most compatible biodegradable polymers depending on the endpoint biological uses based on their specific physicochemical, biomechanical and enzymatic/hydrolytic degradation properties.^[@R18]^ In fact, significant efforts, time and resources are required to engineer biomaterial with unique properties towards development of sophisticated biotherapeutics. Further, the currently implemented biomaterials in various clinical settings need to be revisited to address all the issues associated with application of biopolymers in vivo. Most of these issues are in close association with the physicochemical interaction of the applied biopolymers with the target tissue/cells. Of these, for instance, inadvertent immunologic reactions can dramatically limit their uses while such drawback can be beneficial when the endpoint objective is the activation of immune system by vaccination/immunization. Besides, compelling evidence on long term safety of these materials seems to be necessary. In this review, we highlight the importance of biodegradable polymers and the key issues that have crucially contributed to their limits/slow evolution towards thier applications in biomedical/pharmaceutical fields.

Structural properties of biodegradable polymers {#s2}
===============================================

Structurally, biodegradable polymers possess bonds (i.e., ester, amide, or ether bonds) which are cleavable enzymatically or hydrolytically. Based upon their synthesis methodologies, biodegradable polymers can be categorized into (*i*) natural (e.g., fibrin, collagen, gelatin, cellulose, hyaluronan, pectin), (*ii*) semisynthetic (e.g., chemically modified natural polymers such as chitosan), and (iii) synthetic \[e.g., poly(lactic acid)(PLA), poly(glycolic acid)(PGA), poly(lactic-*co*-glycolic acid)(PLGA), poly(ℇ-caprolactone)(PCL), poly(dioxanone)(PDO), poly(anhydrides), poly(trimethylene carbonate), poly(ortho esters) and poly(phosphazenes)\].

It should be stated that a polymer with a C-C backbone can resist the degradation, while heteroatom-containing polymers can show some degrees of biodegradability depending on the structural properties of the polymer. Hence, inclusion of degradable chemical linkages (e.g., ester, amide and anhydride) can improve the degradation processes. Technically, several intrinsic physicochemical and formulation properties (e.g., structural chemistry, molecular weight, hydrophilicity/hydrophobicity, water absorption, surface charge, type and morphology of formulation, surface modification, and degradation and erosion mechanism) of degradable polymers can affect their compatibility and interaction with biological settings. [Fig. 1](#F1){ref-type="fig"} illustrates the chemical structures of some selected important biodegradable polymers used in various biomedical applications.
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Natural biopolymers {#s2-1}
-------------------

The natural biodegradable polymers, known as biopolymers, encompass various classes of counterparts such as polysaccharides (e.g., starch, cellulose, chitin, chitosan) and naturally existing proteins (e.g., collagen, laminin and fibronectin). Nowadays, many researches have been directed towards the use of natural polymers,^[@R19]^ which are particularly suitable for medical and pharmaceutical applications due to their biocompatibility and biodegradibility.^[@R20]^ [Fig. 1](#F1){ref-type="fig"} epitomizes some commonly used natural biodegradable polymers.^[@R17],[@R21]^ Natural polymers blending with synthetic polymers (e.g., poly(vinyl alcohol), poly(ethylene oxide), poly(vinyl pyrrolidone)) provide possibility for fabrication of bioartificial/biosynthetic polymers as a new class of advanced materials with improved mechanical properties and biocompatibility in comparison with those of single components. This class of biomaterials can be tailored to adequately mimic human tissue components, and are applicable in cell-based transplantation, tissue engineering and gene therapy.^[@R22]^ For example, chemically modified hyaluronic acid and gelatin is investigated to deliver the mesenchymal stem cells to repair the osteochondral defects in a rabbit model. After 12 weeks, defects were completely ameliorated with the cartilage and repaired.^[@R23]^

Synthetic degradable polymers {#s2-2}
-----------------------------

There exist various synthetic biodegradable polymers such as (poly(hydroxylbutyrate), poly anhydride copolymers, poly(orthoester)s, polyphosphazenes, poly(amidoester)s, poly(cyano acrylate)s and PLGA.^[@R14],[@R24],[@R25]^ PLGA is a widely used polymer that has been approved by the United State Food and Drug Administration (FDA) for various therapeutic/diagnostic applications. This class of polymers offer enormous potentials as drug carriers, in large part due to their biodegradability, biocompatibility, and possibility for development of sustained-/controlled-/pulsatile-release and targeted delivery.^[@R14],[@R24],[@R26]^ [Table 1](#T1){ref-type="table"} represents some clinical trials that have used PLGA as delivery system. It should be noted that PLGA undergoes hydrolytic degradation in aqueous environment where ester linkages along with the polymer backbone are randomly hydrolyzed. The ratio of lactic acid (LA) to glycolic acid (GA) plays an important role in degradation mechanism of the PLGA. Additionally, degradation rate and accordingly drug release rate can be manipulated by varying the ratio of LA to GA. For instance, PLGA 50:50 degrades at a faster rate in comparison with PLGA 85:15 due to the higher hydrophilic GA content of the copolymer.^[@R25],[@R27]-[@R29]^ The attractive features of PLGA-based NPs/NSs (e.g., small size, high structural integrity, stability, ease of fabrication, tunable properties, sustained-/controlled-release capability, and surface functionalization characteristics) make them versatile therapeutic delivery vehicles. However, there exist some drawbacks for the PLGA-based NPs in terms of physiochemical and biological properties that limit their applications in pharmaceutical/biomedical fields. These pitfalls include (a) poor loading efficiency for hydrophobic drugs, (b) high burst release, (c) uptake by the reticuloendothelial system (RES), (d) poor stability in water, (e) difficulties in producing particles below 100 nm in diameter, (f) less circulation time in the body, (g) aggregation, and (h) manufacturing scale-up issues. To resolve such constraints, the main focus is now on the development of hybrid PLGA NPs.^[@R30]-[@R32]^ Technically, PLGA NPs can be formulated by emulsification--diffusion, solvent emulsion--evaporation, interfacial deposition, or nanoprecipitation methods.^[@R33]^ However the scale-up process of PLGA NPs' formulation by means of these methods appears to be costly.

###### Application of PLGA in clinical trials^a^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------- ------------------------------------------------------
  **Clinical trial identifier and description**                                                                                                                           **Application**                                                            **Drug/Device**                                            **Phase; status**                            **Formulation**

  NCT02487186: Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy                                                                                   Periodontal\                                                               Doxicicline                                                Phase IV; completed                          PLGA microspheres
                                                                                                                                                                          disease                                                                                                                                                                            

  NCT02138110: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A                                                                                      Traumatic acute spinal cord injury                                         Neuro-Spinal Scaffold                                      Phase III;\                                  PLGA scaffold
                                                                                                                                                                                                                                                                                                                currently recruiting participants            

  NCT00836797: Radiographic Assessment of Bone Regeneration in Alveolar Sockets with PLGA Scaffold After Teeth Extraction                                                 Assessment of bone regeneration                                            Alveolar Sockets                                           Phase I;\                                    PLGA bioscaffold
                                                                                                                                                                                                                                                                                                                completed                                    

  NCT01729195: Ankle Syndesmosis Fixation by Antibiotic Releasing Bioabsorbable Screw                                                                                     Ankle fracture                                                             A ciprofloxacin containing bioabsorbable PLGA bone screw   Phase II;\                                   PLGA-based bioabsorbable thread (4.5 mm in diameter)
                                                                                                                                                                                                                                                                                                                completed                                    

  NCT02255188: Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning                                                                              Arterial occlusive disease                                                 Vascular Prosthesis                                        Phase I; currently recruiting participants   Graft type - PLGA/PCL/gelatin poorly permeable layer

  NCT01681381: Evaluate Safety and Effectiveness of the Tivoli^®^ DES and the Firebird2^®^ DES for Treatment Coronary Revascularization                                   Ischemic heart disease; coronary artery lesions; acute coronary syndrome   Tivoli^®^ DES rapamycin-Eluting stent                      currently recruiting participants            Stent coated with a biodegradable polymer (PLGA)

  NCT01753089: Dendritic Cell Activating Scaffold in Melanoma                                                                                                             Melanoma                                                                   WDVAX                                                      Phase I; currently recruiting participants   PLGA scaffold

  NCT02017275: Comparison of BuMA eG Based Bio Degradable Polymer Stent with EXCEL Biodegradable Polymer Sirolimus-eluting Stent in \"Real-World\" Practice (PANDA-III)   Coronary artery disease                                                    BuMA and EXCEL Stent                                       Phase IV; completed                          Biodegradable PLGA coating
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------- ------------------------------------------------------

^a^Data were obtained from clinicaltrials.gov on January 2017.

Biodegradable synthetic polymers with three-dimensional scaffolds are widely used in tissue engineering. Ultrasonically blended suspension of cellulose-nanofibers (CNFs) with PLGA have been fabricated and the obtained scaffolds appeared to possess suitable mechanical strength and biocompatibility for the cultivation of NIH 3T3 cells, which have been used in tissue engineering.^[@R34]^ For example, PLGA coated beta-tricalcium phosphate (β-TCP) scaffold loaded with vascular endothelial growth factor was synthesized and cell proliferation and attachment was investigated. It was found that the scaffold with sustained-and/or localized-release of VEGF could be favorable for bone regeneration in vitro.^[@R35]^

Semisynthetic degradable polymers {#s2-3}
---------------------------------

The morphological and chemical modifications of natural polymers produce semisynthetic polymers that are better suited for processing and production of materials with potential of mineralization and conversion to biomass.^[@R36]^ Chitosan is a semisynthetic natural based polymer that is primarily obtained from chitin, which is the second abundant polysaccharide in nature.^[@R37]^ Chitosan is obtained by deacetylation of chitin in alkaline condition mostly from the shell waste of shrimps, crabs, krills and lobsters.^[@R21]^ Chitosan is soluble in 0.1 N acetic acid and is a positively-charged linear polymer, which can be formulated as homogenous NPs through simple mixing of the polymer with negatively-charged drugs or nucleic acids. Chitosan NPs have shown great advantages, in large part due to their non-immunogenicity and possibility of introducing larger size of genes into host cells in comparison with the viral vectors.^[@R20],[@R38]-[@R41]^ To improve the applicability of chitosan and its various derivatives (e.g., carboxylated, thiolated and acylated structures) for pharmaceutical/biomedical applications, they have so far been decorated with various functional groups such as polyelectrolyte/polyionic complexes.^[@R19]^ Polyelectrolyte complex of chitosan and gelatin hydrogels prepared at pH 6.5 could be optimized for tree-dimensional bioprinting at room temperature.^[@R42]^ Also, the modified chitosan with diacetate and triacetate is used as novel matrix to sustained release of doxorubicin (DOX). NPs loaded with DOX indicated high encapsulation efficiency, sustained-release pattern and enhanced cellular accumulation. Further, chitosan-based NPs could improve the oral bioavailability of DOX.^[@R43]^

Targeted therapy of solid tumors {#s3}
================================

Development and progression of solid tumors are in close relation with Warburg effect and aberrant glucose metabolism through glycolysis resulting in excess production of acidic byproducts whose efflux can deregulate the pH of tumor microenvironment (TME). In solid tumors, cancerous cells upregulate the expression of glucose transporter (GLUT-1) and some key enzymes and transporters (MCT-1, NHE-1, CA IX and H+ pump V-ATPase) to fulfill the high energy requirement. This deviant phenomenon provokes the efflux of protons into extracellular fluid (ECF), acidifying ECF (pH \~6.6), while the pH of cancer cells holds up to about 7.4.^[@R44]^ These anomalous phenomena form a permissive milieu in favor of cancer cells survival, proliferation and invasion. The cocktail of various enzymes with acidic pH can remodel the extracellular matrix (ECM) that favors (a) the epithelial--mesenchymal transition (EMT) process necessary for survival of cancer cells, (b) migration of cancer cells form its primary setting to distant organs/tissues, and (c) formation of TME with altered interstitium in which the interstitial fluid pressure (IFP) is markedly high opposing the permeation and penetration of anticancer agents into the core of solid tumors.^[@R45]^

It is believed that, during metastasis, the EMT process assists cancer cells to avoid anoikis through various mechanisms enabling them to circulate within the blood stream or even lymphatic routes and colonize beyond its primary niches.^[@R46],[@R47]^ Further, neovascularization within solid tumors are often incomplete encompassing non-integrated endothelial cells with pores and gaps (120-1200 nm) between these cells, upon which the tumor vasculature shows an enhanced permeability and retention (EPR) effect.^[@R48],[@R49]^ This latter phenomenon have widely been used for passive targeting of solid tumors^[@R50]^ despite opposing impact(s) of high IFP of TME.^[@R51],[@R52]^

Stimuli-responsive polymers are able to alter their physical properties in response to environmental changes (e.g., temperature, pH, light, ultrasound, etc.), at which they are considered as superior carriers for targeted delivery of drugs to and on-demand drug release at the site of solid tumors.^[@R53]^ The pH difference of TME with normal tissues seems to be the main driving force for development of pH-sensitive DDSs. Biodegradable pH-responsive polymeric carriers in the form of micelles, vesicles or NPs have great potential to provide selective/on-demand drug release at tumor sites, which can be then rapidly degraded with no/trivial undesired impacts. Poly (β-amino ester) as a biodegradable cationic polymer is used in development of pH-sensitive DDSs. At low levels of pH (≤6.5), the polymer dissolves rapidly and releases the drug.^[@R54]^ Hydrogels based on PCL, methacrylic acid (MAA), and Pluronic is developed as a potential biodegradable polymer for drug delivery uses. The hydrolytic degradation behavior of hydrogel was shown to be enhanced with the increase of PCL mainly due to the acid cleavage of ester bonds.^[@R55]^ Biodegradable polymeric micelles composed of PEG and polycarbonate functionalized with disulfide and carboxylic group can be synthesized as pH and redox dual responsive DDS. The DOX-loaded micelles with small particle size and narrow size distribution indicate high drug loading capacity. When NPs were exposed to the endosomal pH of 5.0, DOX release rate was found to be accelerated by at least two-fold. The DOX-loaded micelles showed enhanced cytotoxicity in nude mice bearing BT-474.^[@R56]^

Hydrophilic thermo-sensitive biodegradable polymeric nanocarriers, as another example of smart DDSs, are collapsed at hyperthermic condition of 42°C which causes greater drug release and may lead to a synergistic effect of chemotherapy and hyperthermia for treatment of solid tumors.^[@R57],[@R58]^ A new pH-/temperature-sensitive, biocompatible, biodegradable, and injectable hydrogel based on poly(ethylene glycol)-poly(amino carbonate urethane) (PEG-PACU) copolymers is developed for the sustained delivery of human growth hormone (hGH). The prepared copolymer is sol at the low pH and temperature (pH 6.0, 23°C), while it forms gel in the physiological condition (pH 7.4, 37°C). In vivo investigation of the prepared hydrogel confirmed the in situ gel formation and controlled degradation at the injection site.^[@R59]^ Wang et al prepared a thermo-sensitive hydrogel of chitosan/hydroxypropyl methylcellulose/glycerol and the hydrogel showed the in situ gel formation at physiological condition (pH ranging from 6.8 to 6.9 at 37°C). The synthesized hydrogel indicated low toxicity, good fluidity, thermosensitivity, biodegradability and controlled-release of bovine serum albumin.^[@R60]^

Furthermore, the biodegradable polymeric carriers have been modified by tumor targeting agents such as specific ligands (e.g. folic acid),^[@R61]^ antibodies^[@R28]^ and aptamers^[@R62]^ to enhance the NPs translocation into tumor cells. PEG-PCL-PEG thermo-sensitive hydrogel containing a tumor-targeted biodegradable folate-poly(ester amine)/DNA complexes has been synthesized and investigated for targeted gene delivery. The hydrogel composite indicates slight cytotoxicity with high transfection efficiency in vitro. The synthesized hydrogel with sustained gene release and local gene delivery could met the demand for the effective tumor-targeted gene delivery system.^[@R63]^

Taken all these issues into consideration, it seems that the effective therapy of cancer demands specific targeting of the cancerous cells by smart NSs and delivery of anticancer agents to the target cells but not the healthy normal cells. An efficient delivery of anticancer drugs specifically to solid tumors requires implementation of nanocarriers with high payload capacity and suitable permeability and degradability within the TME.^[@R64],[@R65]^ Advanced biodegradable NSs armed with homing devices have the ability to penetrate into TME and target the cancerous cells solely while they impose no/little effects on the healthy cells and immunosurveillance activity of the immune system.^[@R14],[@R45],\ [@R66]-[@R68]^ [Fig. 2](#F2){ref-type="fig"} represents schematic structures of advanced DDSs and multifunctional NSs used for targeted therapy of cancer.
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It should be also pointed out that because of the wide-range applications and different properties of the polymeric biomaterials, there is no ideal polymer with universal use. Hence, depending on the endpoint use of the biopolymer, the right structure and formulation must be selected/devised while there exists an array of macromolecular biomaterials that may meet the need(s) for development of therapeutic NSs. Biodegradable polymers, no matter synthetic or natural, can be degradable in vivo into biocompatible by-products through enzymatic transformation (e.g., hydrolysis).^[@R17]^ Several factors (chemical structure and composition, distribution of repeat units in multimers, presence of ionic groups, structural configuration, molecular weight, morphology and pH) can affect the biodegradation process of polymeric system.^[@R25],[@R70]^ Hence a better understanding about all these influencing factors can facilitate the development of advanced DDSs and multimodal NSs. As shown in [Table 2](#T2){ref-type="table"}, several biodegradable polymeric nano-formulations are under investigation for treatment of the wide spectra of diseases. Further, the biodegradability of these polymers make them as the safest implantable systems that can be degraded, and hence need no subsequent surgical operation to removal of transplanted system.^[@R17]^ A multilayer cylindrical implant made of PLGA was used for the controlled- and extended-release of DOX molecules in murine breast cancer. This implant system compared to the DOX traditional IV route, could delivered greater amount of DOX with better coverage of local tumor, preventing metastatic spread and less drug toxicity without weight loss, splenomegaly and cardiac toxicity.^[@R79]^

###### In vivo investigation of some selected biodegradable polymeric nano-formulations for clinical application

  ------------------------------- ----------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------
  **Polymer**                     **Encapsulant**   **Formulation method**                  **In vivo biological impacts**                                                                                  **Ref.**

  PLA                             Hemoglobin        Double emulsion method                  Reduced lever accumulation                                                                                      ^[@R60]^

  PLA                             Ellagic acid      Emulsion diffusion evaporation method   NPs protected the cyclosporin induced nephrotoxicity in rats                                                    ^[@R61]^

  PCL                             Tamoxifen         Solvent displacement                    Increased level of accumulation of the drug within tumor with time and extended their presence in circulation   ^[@R62]^

  Gelatin                         Paclitaxel        Desolvation method                      Paclitaxel-loaded NPs were active against human RT4 bladder transitional cancer cells                           ^[@R63]^

  Alginate/Chitosan               Insulin           Ionotropic\                             NPs adhere to intestinal epithelium and internalized by intestinal mucosa                                       ^[@R64]^
                                                    gelation method                                                                                                                                         

  Chitosan                        Cyclosporin A     Ionic gelation\                         Cyclosporin A concentration were higher incornea than conjunctiva                                               ^[@R65]^
                                                    method                                                                                                                                                  

  Poly(*n*-butyl cyanoacrylate)   Indomethacin      Interfacial polymerization              Permeate through rats skin in a period of 8 h                                                                   ^[@R66]^

  Glycol chitosan                 Doxorubicin       Self-assembling                         Self-aggregates loaded with doxorubicin exhibited lower toxicity than free doxorubicin                          ^[@R67]^
  ------------------------------- ----------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------

Biodegradable scaffolds composed of PLA and β-tricalcium phosphate is developed for complex maxillofacial reconstruction. Biocompatibility tests with mesenchymal stem cells indicated better proliferation, without toxicity. The porous interconnected structures make possible cellular adhesion and vascular proliferation. The in vivo investigation in rats led to complete bone ingrowth within 30 days with minimal inflammatory impacts.^[@R80]^

Final remarks {#s4}
=============

To engineer the most compatible biomaterials, a number of central characteristics need to be met. These materials must (a) pose no/trivial inflammatory response; (b) possess a degradation time coinciding with their function; (c) have appropriate mechanical properties for their intended use; (d) produce nontoxic degradation products that can be readily reabsorbed or excreted; and (e) include appropriate permeability and processability for designed application.^[@R81]^ These properties are greatly affected by a number of features of degradable polymeric biomaterials including, but not limited to: material chemistry, molecular weight, hydrophobicity, surface charge, water adsorption, degradation and erosion mechanism.

Due to the wide range use of polymeric biomaterials, a single, ideal polymer or polymeric family does not exist. Instead a library of materials is available to researchers that can be synthesized and engineered to best match the specifications of the material's desired biomedical function. Current efforts in biodegradable polymer synthesis have been focused on custom designing and synthesizing polymers with tailored properties for specific applications by: (i) developing novel synthetic polymers with unique chemistries to increase the diversity of polymer structure, (ii) developing biosynthetic processes to form biomimetic polymer structures and (iii) adopting combinatorial and computational approaches in biomaterial design to accelerate the discovery of novel resorbable polymers.

Taken all, it should be taken into consideration that an ideal biodegradable polymeric DDS must be tailored in a way that it provides a number of imperative characteristics such as (a) suitable permeability and drug release profile based on physicochemical properties (e.g., lipophilicity and hydrophilicity) of cargo molecules, (b) biodegradability and biocompatibility, (c) tensile strength, and (d) possibility for surface modification and decoration.^[@R17]^ It should be also pointed out that, for broadening the potential applications of biodegradable polymers, they should be modified utilizing several methods such as random and block copolymerization, grafting, blending and composites forming, which lead to new advanced biomaterials with unique properties including high performance, low cost, and good processability.^[@R82]^

Given the fact that various non-biodegradable polymers and lipids used as DDSs and/or gene delivery systems (GDSs) impose intrinsic inadvertent cytotoxic and genotoxic impacts^[@R1]-[@R4],\ [@R83]-[@R87]^ and some inevitable downsides of the currently used biodegradable polymers, we need to advance DDSs/GDSs towards mimicking the natural polymers found in human body. Perhaps, it is the right time to move on and implement the biopolymers of the human body, and engineer human-origin polymeric scaffolds to be able to specifically deliver drugs into the target cells/tissue without any detrimental impacts on the healthy normal cells by delivery vehicles *per se*.
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Review Highlights {#s8}
=================

What is current knowledge?√ Biodegradable polymers (synthetic, semi-synthetic and natural) used for development of NPs possess unique characteristics including nanoscaled structures, high encapsulation capacity, biocompatibility and controlled-/sustained-release profile for lipophilic/hydrophilic drugs.√ PLGA based NPs as a synthetic biodegradable polymeric system, is FDA approved and used widely.√ Chitosan as a semisynthetic natural based polymer can be chemically modified to improve its applicability for various pharmaceutical/biomedical applications.What is new here?√ Advanced biodegradable NSs armed with homing devices have ability to penetrate into TME and target the cancerous cells solely with no/little effects on the healthy cells.√ Stimuli-responsive biopolymeric NSs offer selective drug release at tumor sites.
